Deep dive: AAP updates 2026-2027 COVID-19 vaccine recommendations for infants and children — what parents should know

Background. COVID-19 continues to circulate, and young children remain at elevated risk of severe disease relative to older kids. Hospitalization rates for infants 6–23 months have been comparable to those in adults 65 and older in some seasons. The American Academy of Pediatrics (AAP) publishes annual recommendations aligned with circulating variants and updated formulations.

In September 2026 the AAP issued preliminary guidance; on 19 October 2026 it published the formal policy statement and technical report in Pediatrics. These documents update dosing for the 2026–2027 season.

What changed. The AAP recommends that all infants and children 6 through 23 months of age who do not have contraindications receive the 2026–2027 COVID-19 vaccine:

For children and adolescents 2 through 18 years, a single dose is recommended for those at increased risk of severe COVID-19 (including certain underlying conditions, residents of congregate settings, never-vaccinated children, and those whose household contacts are high-risk). Moderately or severely immunocompromised children 6 months–18 years need two or more doses depending on history. Children 2–18 years not in a risk group whose parents want protection should be offered a single dose.

Any age-appropriate formulation (mRNA or protein subunit) can be used; the most recent version available should be preferred. Contraindications remain a history of severe allergic reaction to a previous dose or component.

Competing viewpoints. Some public-health agencies and clinicians emphasize that the highest absolute risk is concentrated in the youngest infants and in older children with specific medical conditions, supporting a risk-based approach for ages 2+. Others note that uptake among eligible hospitalized children has been low (under 4% up to date in one analysis) and argue that offering the vaccine more broadly reduces missed opportunities. Real-world data from the 2024–2025 season showed updated doses cut emergency and urgent-care visits substantially in younger age groups. Myocarditis rates with newer formulations have declined. Critics of universal recommendations for the youngest point to very low absolute rates of severe outcomes in previously healthy toddlers and call for more individualized counseling; AAP and many pediatric groups counter that the risk–benefit still favors vaccination given the observed hospitalization burden and the safety profile of current products.

What to watch next. Clinic uptake during the early respiratory season, especially for the 6–23 month universal recommendation. Availability of the newest formulations and any supply constraints. How state and local health departments communicate the AAP guidance relative to CDC schedules. Overlap with flu and RSV immunization windows. Longer-term data on duration of protection and any updates if new variants emerge. Parents should discuss timing with their pediatrician, particularly if the child has a recent COVID-19 infection or other vaccines due.

This is editorial context for parents, not medical advice. Confirm recommendations and any contraindications with your child’s clinician or local public-health guidance.